Leqvio (inclisiran) / Alnylam, Novartis - LARVOL DELTA

PCSK9 Inhibitors Added to Moderate/High-Intensity Statin Therapy Are Associated With Improved Liver-Related Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (ACG 2026) - "We compared patients who initiated a PCSK9 inhibitor (alirocumab, evolocumab, or inclisiran) at least 3 months after MASLD diagnosis (n=10,940) versus those on M/HI statins alone (n=604,717). After PSM, 10,216 patients per group were identified (Table 1). Median follow-up was 516 vs. 485 days."

Clinical • CNS Disorders • Dyslipidemia • Familial Hypercholesterolemia • Fibrosis • Gastroenterology • Genetic Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Tumor

The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive Review. (PubMed, Reports (MDPI)) - " These cases illustrate that inclisiran can effectively lower LDL-C levels across primary and secondary prevention settings in PWH facing oral therapy limitations or statin intolerance. Provider-administered dosing every 6 months overcomes adherence challenges, supporting the inclusion of PWH in broader clinical pathways pending ongoing cardiovascular outcome trials."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Myocardial Infarction • CD4

Comment on "Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials". (PubMed, Int J Cardiol Cardiovasc Risk Prev) - No abstract available

Journal • Retrospective data

Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials (ESC 2026) - "Purpose: To investigate the efficacy and safety of non-statin treatments—including evolocumab, alirocumab, enlicitide, inclisiran, evinacumab, omega-3 fatty acids, and ezetimibe—in high CV risk patients without previous stroke. Evolocumab had the potential to be the first-line non-statin option for high CV risk patients without previous stroke due to its efficacy in reducing MACE, CV mortality, LDL-C, and Lp(a)."

Retrospective data • Cardiovascular • Dyslipidemia • Myocardial Infarction

Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets. (PubMed, Front Med (Lausanne)) - "Third evidence indicates that non-statin therapies-including ezetimibe, bempedoic acid, PCSK9 inhibitors (evolocumab and alirocumab), and inclisiran-provide substantial LDL-C reductions and reduce cardiovascular events...Additionally, the fixed-dose combination of bempedoic acid and ezetimibe produces an approximately 36.2% reduction in LDL-C in high-risk patients...Furthermore, inflammation (measured by hsCRP) provides complementary prognostic information beyond LDL-C. This expert position paper proposes practical algorithms for a precision medicine approach in Latin America, matching treatment intensity to individual risk profiles for the primary and secondary prevention of atherosclerotic cardiovascular disease."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • CRP

The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction (ESC 2026) - "In patients with ischaemic HFrEF on maximal statin/ezetimibe therapy, Inclisiran was significantly more effective than Evolocumab in achieving the stringent LDL-C target of <55 mg/dL at 5 months, with a favourable safety profile and less frequent dosing. These findings support Inclisiran as a potent and convenient lipid-lowering strategy in this high-risk cohort"

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiovascular

Comparative LDL-C Reduction and Cardiovascular Outcomes With PCSK9-Pathway Therapies: A Systemic Review and Network Meta-Analysis (ESC 2026) - "Injection-site reactions were lowest with lerodalcibep and highest with inclisiran. SUCRA rankings for injection-site reactions favored lerodalcibep, followed by alirocumab/evolocumab, with inclisiran ranking lowest.ConclusionPCSK9-pathway therapies significantly reduce LDL-C, with lerodalcibep demonstrating the greatest lipid-lowering effect, while only evolocumab and alirocumab show definitive MACE reduction; overall safety profiles were comparable across agents."

Retrospective data • Review • Cardiovascular • Dyslipidemia

A case report of young-onset type 2 diabetes patient with severe metabolic dysregulation carrying an LRP6 variant. (PubMed, Front Endocrinol (Lausanne)) - "Multidisciplinary treatment-incorporating acute-phase plasma exchange, ω-3 fatty acid ethyl ester 90, inclisiran, subcutaneous insulin aspart pump therapy, metformin, insulin icodec, finerenone, and Huangkui capsules-led to improvements in the patient's metabolic indicators. This case emphasizes that genetic variant screening should be considered in patients with unexplained severe metabolic disturbances, particularly those with early-onset disease. This case also provides a foundation for future functional studies and genetic confirmation."

Journal • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Nephrology • Pancreatitis • Renal Disease • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Genetic and Conventional Risk Stratification Are Complementary for Primary Prevention of CAD. (PubMed, Methodist Debakey Cardiovasc J) - "This is considered the minimum clinical threshold based on a 1% incidence of myocardial infarction in the United States (US) at age 40 years and an average plasma LDL-C of 125 mg/dL, with a product of 40 × 125 resulting in 5,000 mg years. Utilizing PRS to detect candidates at increased risk for CAD while in their 30s, followed by an annual injection of a long-acting agent such as inclisiran to reduce plasma LDL-C in the range of 60 mg/dL, has the potential to delay the onset of a first myocardial infarction until age 80 years."

Biomarker • Journal • Review • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

Lipid-Lowering Effects of Inclisiran in Statin- or PCSK9i Monoclonal Antibody-Intolerant Individuals. (PubMed, J Am Heart Assoc) - No abstract available

Journal

Secondary prevention lipid management after ACS at a DGH: a quality improvement project. (PubMed, Br J Cardiol) - "Many patients fail to achieve therapeutic lipid lowering. Strategies to address this are urgently required."

Journal • Acute Coronary Syndrome • Cardiovascular

Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies. (PubMed, Am J Cardiovasc Drugs) - "PCSK9 inhibitors and inclisiran produce modest (approximately 20-30%) Lp(a) reductions, and lipoprotein apheresis may be useful in highly selected patients, but none represents a broadly applicable Lp(a)-specific therapy...Antisense oligonucleotides, small interfering RNA therapies and oral small-molecule inhibitors have demonstrated profound and durable Lp(a) reductions, frequently exceeding 80-100% with small interfering RNA (siRNA)-based agents (olpasiran, zerlasiran, lepodisiran), up to 80% with the antisense oligonucleotide pelacarsen, and up to 85% with the oral small-molecule muvalaplin, in phase 1 and phase 2 clinical trials...Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran). This narrative review summarizes the biology and epidemiological relevance of Lp(a),..."

Journal • Review • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Ischemic stroke • Myocardial Infarction • Peripheral Arterial Disease

Magnetic particle imaging of macrophage phagocytosis evaluates plaque vulnerability and therapeutic efficacy in atherosclerosis (ESC 2026) - "After 10 weeks of treatment with a proprotein convertase subtilisin/kexin type 9 inhibitor (inclisiran) or a sodium-glucose cotransporter-2 inhibitor (empagliflozin), macrophage phagocytosis and several features of plaque vulnerability were assessed by PESPION-enhanced MPI and histopathology, respectively. Macrophage scavenger receptor 1 (MSR1) was identified as a key phagocytosis marker for plaque vulnerability. MSR1 is a key mediator of phagocytic activity in plaque vulnerability. PESPION-enhanced MPI provides as a sensitive, non-invasive tool for quantifying MSR1-mediated macrophage phagocytosis, enabling the robust evaluation of plaque vulnerability and pharmacological response."

Clinical • Atherosclerosis • Cardiovascular • APOE • MPO

Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC/AHA Dyslipidemia Guideline: What Is New and Why It Matters. (PubMed, Curr Atheroscler Rep) - "Major updates include reintroduction of goal-directed therapy, lower LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) targets, and broader use of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, bempedoic acid, and inclisiran. The guideline also emphasizes structured lipid monitoring and a systematic approach to statin-attributed muscle symptoms to reduce therapeutic inertia, preserve effective lipid-lowering therapy, and support sustained goal attainment. Collectively, these updates mark a transition toward precision lipidology, emphasizing individualized risk assessment, earlier treatment escalation, structured follow-up, preservation of effective therapy despite treatment-related symptoms, and more comprehensive reduction of residual cardiovascular risk in secondary prevention."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOB

[Translated article] Concordance between the theoretical and real stratification of the ability-motivation-opportunity model in patients with cardiovascular pathologies. (PubMed, Farm Hosp) - "There is agreement between both distributions, which supports the applicability of the tool in healthcare practice, and it can be used to prioritize resources in outpatient consultations."

Journal • Cardiovascular

MWX203-II-DLP: Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia (clinicaltrials.gov) - P2 | N=216 | Recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P2 trial • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia • APOB

RNA Interference Therapy with Inclisiran versus Statin Intensification in Peripheral Artery Disease: Limb Salvage and Major Adverse Cardiovascular and Limb Events: A Systematic Review and Meta-Analysis (AHA 2026) - "Abstract is embargoed at this time."

Retrospective data • Review • Cardiovascular • Peripheral Arterial Disease

Comparative Lipid Outcomes with Inclisiran versus PCSK9 Monoclonal Antibodies in Hypercholesterolemia: A Propensity Score Matches Observational Study (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Observational data • Dyslipidemia • Metabolic Disorders

Cardiovascular Outcomes of Inclisiran in Patients with Elevated Cardiovascular Risk and Metabolic Dysfunction Associated Steatotic Liver Disease (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Cardiovascular • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran. (PubMed, Rev Cardiovasc Med) - "The objective is to provide evidence to guide the appropriate clinical use of inclisiran, a novel option for lipid-lowering therapy. Inclisiran may represent another milestone in the treatment of dyslipidemia."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

SEsiR-ACS: Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome (clinicaltrials.gov) - P4 | N=294 | Not yet recruiting | Sponsor: Seoul National University Bundang Hospital

New P4 trial • Acute Coronary Syndrome • Cardiovascular

Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial (ESC 2026) - No abstract available

Clinical • Head-to-Head • Late-breaking abstract • P4 data • Cardiovascular

Digital phenotyping and additive multimorbidity scoring to operationalise very-high-risk secondary prevention in primary care (ESC 2026) - " Within a primary care population of 10,306 adults, a standardised electronic search (CVDPL2F) identified patients with established ASCVD (CHD, PCI/stent, PAD, stroke/TIA), excluding familial hypercholesterolaemia and those using inclisiran, with LDL-C >1.8 mmol/L or non-HDL >2.5 mmol/L (2)... Digital phenotyping identified a concentrated, very-high-risk ASCVD cohort with substantial multimorbidity and modifiable care gaps. The CVRM score provides a scalable prioritisation framework for structured community-based secondary prevention. A prospective longitudinal evaluation is underway to quantify intervention intensity (pharmacological and lifestyle) and the associated change in mean CVRM score, providing an objective measure of individualised care-gap modification within primary care."

Clinical • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Hypertension

Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial (ESC 2026) - "At screening, they had either received stable-dose statin with or without ezetimibe for ≥ 4 weeks, or no lipid-lowering therapy for ≥ 4 weeks. SYH2053 exhibited rapid, stable and sustained reductions in LDL-C and PCSK9 in primary hypercholesterolemia or mixed dyslipidemia pts. At an equivalent dose of 300 mg, SYH2053 may yield greater reductions in LDL-C and PCSK9 compared with inclisiran. These observations warrant further-validation in future phase III clinical trial."

Clinical • P2 data • Cardiovascular • Dyslipidemia